Colorado · 81240

Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant in Colorado

Colorado Medicare Avg
$64.34
0% above national avg
National Medicare Avg
$64.31
All states combined
Billed Charge (CO)
$311.07
What providers submit
Est. Commercial (CO)
$147.98
National avg: $144.05
Est. Cash / Self-Pay (CO)
$133.80
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

301
Services in CO
6
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Colorado

Provider Medicare Services
Esoterix, Inc $64.31 185
Quest Diagnostics Clinical... $64.38 53
University Physicians, Incorporated $64.38 41
Laboratory Corporation Of America $64.38 20

Colorado Pricing in Context

In Colorado, CPT code 81240 (Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant) carries an average Medicare payment of $64.34 — 0% above the national benchmark of $64.31. 6 providers across the state submitted claims for this procedure in 2023, performing 301 total services. Individual payments in CO ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Colorado is $311.07, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Colorado sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Colorado lands near $147.98, with self-pay cash prices typically around $133.80. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant cost in Colorado?

The average Medicare payment for Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant in Colorado is $64.34, which is 0% above the national average of $64.31. Providers in CO typically bill $311.07 for this procedure.

What does Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant cost with insurance in Colorado?

With commercial insurance in Colorado, Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant costs an estimated $147.98. Without insurance, the estimated cash price is $133.80. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant in Colorado?

6 providers in Colorado billed Medicare for Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant in 2023, performing 301 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant cheaper in Colorado than the national average?

No — Gene Analysis (prothrombin, Coagulation Factor Ii) A Variant costs 0% above the national average in Colorado. The state average Medicare payment is $64.34 compared to $64.31 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial